in this issue
Regions :: India/Pakistan
FDA prohibits Ranbaxy API plant from producing and distributing products for US market
4:15 AM MST | January 24, 2014 | Deepti Ramesh
The US Food and Drug Administration (FDA) announced on 23 January that it has notified Ranbaxy Laboratories (Gurgaon, India), that it is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility at Toansa, India, for FDA-regulated drug products. The Toansa facility is now subject to certain terms of a consent decree of permanent injunction entered against Ranbaxy in January 2012. The decree contains provisions to ensure compliance with current good manufacturing practice (cGMP) requirements at Ranbaxy facilities at...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee